KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.

Arun A Azad, Daniel P Petrylak, Taro Iguchi, Neal D Shore, Arnauld Villers, Francisco Gomez-Veiga, Antonio Alcaraz, Boris Alekseev, Russell Z Szmulewitz, Jeffrey Holzbeierlein, Brad Rosbrook, Jie Ma, Fabian Zohren, Nader N El-Chaar, Gabriel P Haas, Arnulf Stenzl, Andrew J Armstrong

JAMA Netw Open 8(5) e258751

PMID40332939
PMCIDPMC12059972
DOI10.1001/jamanetworkopen.2025.8751
发表日期2025-05-07
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

IMPORTANCE: In men with metastatic hormone-sensitive prostate cancer (mHSPC), prostate-specific antigen (PSA) decline after treatment has been associated with improved survival. However, the data on PSA decline are limited in men with mHSPC after treatment with enzalutamide plus androgen deprivation therapy (ADT). OBJECTIVE: To evaluate the association of enzalutamide plus ADT in men with mHSPC by PSA level at study enrollment in individuals with prior ADT and by degree of PSA reduction with clinical end points. DESIGN, SETTING, AND PARTICIPANTS: This post hoc secondary analysis was performed on data collected from the ARCHES multinational, double-blind, phase 3 randomized clinical trial. In the ARCHES trial, men with mHSPC were randomized between March 21, 2016, and January 12, 2018. Analyses were performed in October 2018 (median follow-up, 14.4 months; IQR, 11.2-17.7 months) and May 2021 (median follow-up, 44.6 months; IQR, 41.3-48.6 months). INTERVENTION: Patients were randomized 1:1 to enzalutamide (160 mg/d) plus ADT or placebo plus ADT. ADT received for 3 to 6 months before study enrollment was permitted. MAIN OUTCOMES AND MEASURES: Radiographic progression-free survival (rPFS) and overall survival (OS) were correlated post hoc with PSA level at enrollment in patients with prior ADT and additionally with PSA decline at 6 months or undetectable PSA (<0.2 ng/mL) during study treatment. RESULTS: A total of 1150 men (median age, 70 years; range, 46-92 years) were enrolled. Improvement in clinical outcomes such as rPFS was seen with enzalutamide plus ADT in men with PSA levels at enrollment of 0.2 to 4 ng/mL and above 4 ng/mL. Hazard ratios (HRs) for improved rPFS in men with PSA levels up to 0.2 ng/mL, above 0.2 to 4 ng/mL, and above 4 ng/mL were 0.59 (95% CI, 0.27-1.30), 0.32 (95% CI, 0.20-0.50), and 0.44 (95% CI, 0.32-0.62), respectively. Patients treated with enzalutamide plus ADT who achieved undetectable PSA had an 86.0% reduced risk of radiographic disease progression (HR, 0.14 [95% CI, 0.09-0.23]; P < .001) and a 76.0% reduced risk of death (HR, 0.24 [95% CI, 0.17-0.34]; P < .001). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, patients with mHSPC treated with enzalutamide plus ADT vs placebo plus ADT had improved clinical outcomes regardless of PSA level at enrollment. Undetectable PSA was associated with improved clinical outcomes with enzalutamide treatment. Future studies are required to further characterize the clinical utility of further treatment intensification among men with mHSPC for whom ADT plus enzalutamide fails to achieve undetectable PSA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02677896.

KM 提取结果

4 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2.. Kaplan-Meier Plots of Overall Survival (OS) Adjusted for Crossover by Prostate-Specific Antigen (PSA) Categories (≤0.2, >0.2-4, or >4 ng/mL) at Study Enrollment Analysis was conducted in intention-to-treat patients with prior androgen deprivation therapy (ADT) use. The data cutoff date was May 28, 2021. Events were death from any cause. Time from randomization to death from any cause. For patients still alive at the date of the analysis cutoff point, OS was censored on the last date the patient was known to be alive. For the overall population, the log-rank test was stratified by treatment group, volume of disease, and prior docetaxel use. Within each treatment group, the log-rank test was stratified by volume of disease and prior docetaxel use. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.

A

Overall Survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall Survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
C

Overall Survival

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start
查看结果
KM Figure2 个面板

Figure 3

Figure 3.. Kaplan-Meier Plots of Radiographic Progression-Free Survival (rPFS) and Overall Survival (OS) by Prostate-Specific Antigen (PSA) Decline (to < 0.2, 0.2-4, or >4 ng/mL) at 6 Months Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline and available 6-month PSA values. The data cutoff date was May 28, 2021. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.

A

rPFS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
B

OS

Figure 3 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Figure 4

Figure 4.. Kaplan-Meier Plot of Time to Achieve Undetectable Prostate-Specific Antigen (PSA) by Treatment Group Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline. The data cutoff date was October 14, 2018. Note that the additional patient in the placebo plus ADT group was included at the later data cutoff date of May 28, 2021. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.

Figure_4

Time to Achieve Undetectable PSA

Figure 4 · Panel Figure_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_4 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
KM Figure2 个面板

Figure 5

Figure 5.. Kaplan-Meier Plots of Radiographic Progression-Free Survival (rPFS) and Overall Survival (OS) by Prostate-Specific Antigen (PSA) Decline to Undetectable ( < 0.2 ng/mL) at Any Time During the Treatment Period Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline. Events were death from any cause. Time from randomization to death from any cause. For patients still alive at the date of the analysis cutoff point, OS was censored on the last date the patient was known to be alive. The data cutoff dates for OS and rPFS were May 28, 2021, and October 14, 2018, respectively. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.

A

rPFS

Figure 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Figure 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Efficacy Outcomes of Enzalutamide Plus Androgen Deprivation Therapy (ADT) vs Placebo Plus ADT in Prostate-Specific Antigen (PSA) Categories (≤0.2, >0.2-4, or >4 ng/mL) at Study Enrollment Analysis was conducted in intention-to-treat patients with prior ADT use. The data cutoff date was May 28, 2021 (median follow-up, 44.6 months; IQR, 41.3-48.6 months). To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio; ICR, independent central review; NR, not reached; OS, overall survival; QOL, quality of life; rPFS, radiographic progression-free survival.
非 KM Figure